Libo Pharma Corp. (TPEX:7888)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
39.35
-0.15 (-0.38%)
At close: May 29, 2026
Market Cap2.96B
Revenue (ttm)n/a
Net Income-296.30M
EPS-4.74
Shares Out 75.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume164,005
Open38.95
Previous Close39.50
Day's Range38.00 - 39.45
52-Week Range35.70 - 69.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJun 18, 2026

About Libo Pharma

Libo Pharma Corp., a clinical-stage biopharmaceutical company, engage in novel therapeutics development in the field of oncology and hematology. The company offers LIB-101, an interleukin-12 (IL-12) cytokine immunotherapy for innate immunity, adaptive immunity, and hematopoiesis. Libo Pharma Corp. was founded in 2017 and is based in Taipei, Taiwan. [Read more]

Industry Pharmaceutical Preparations
Founded 2017
Employees 31
Stock Exchange Taipei Exchange
Ticker Symbol 7888
Full Company Profile

Financial Performance

Financial Statements